

Amend Claim 16 as follows:

16. (Amended) A method of decreasing atherosclerosis comprising administering to a human or an animal in need thereof an amount of a substance selected from the group consisting of leuprolide acetate, goserelin acetate, flutamide, bicalutamide, and nilutamide, which is an inhibitor of the release of LHRH or GnRH resulting in decreased levels of LH.

leoprolide acetate, goserlin acetate, flutamide, bicalutamide and nilutamide, which is an inhibitor of the release of LHRH or GnRH resulting in decreased levels of LH.

17. A method of decreasing atherosclerosis and its complications including but not limited to myocardial infarction, stroke and peripheral vascular disease comprising administering to an animal or human an amount of Finasteride or other inhibitor of 5 alpha reductase inhibitor or an inhibitor of any subtype of that enzyme resulting in decreased levels of dihydrotestosterone (DHT), in an amount sufficient to reduce atherosclerosis.

C  
18. A method of decreasing atherosclerosis and its complications including but not limited to myocardial infarction, stroke and peripheral vascular disease comprising administering to an animal or human an amount of non-steroidal antiandrogen sufficient to reduce atherosclerosis.

19. The method of Claim 15 comprising administering to a human or an animal an amount of Bicalutamide sufficient to reduce atherosclerosis.

20. The method of Claim 19 wherein the effective amount of Bicalutamide is 50 mg as an oral tablet taken daily.

21. A method of Claim 15 wherein bicalutamide is administered as a tablet, or as part of a liquid solution or dispersion, or patch, or subcutaneous pellet, or intramuscular injection.

22. The method of Claim 15 comprising administering to a human or an animal an amount of Flutamide sufficient to reduce atherosclerosis.

23. The method of Claim 15 wherein the effective amount of Flutamide is 250 mg orally three times a day.

24. A method of Claim 15 wherein flutamide is administered as a tablet, or as part of a liquid solution or dispersion, or patch, or subcutaneous pellet, or intramuscular injection.

25. The method of claim 15 comprising administering to a human or an animal an amount of Nilutamide sufficient to reduce atherosclerosis.

26. The method of Claim 15 wherein the effective amount of Nilutamide is 50 mg orally three times a day.

27. The method of Claim 15 wherein nilutamide is administered as a tablet, or as part of a liquid solution or dispersion, or patch, or subcutaneous pellet, or intramuscular injection, or any other method with the intent of accomplishing systemic absorption of the drug sufficient to reduce atherosclerosis.

28. The method of Claim 15 wherein nilutamide is administered as a tablet, or as part of a liquid solution or dispersion, or patch, or subcutaneous pellet, or intramuscular injection, or any other method with the intent of accomplishing systemic absorption of the drug sufficient to reduce atherosclerosis.

29. A method of decreasing atherosclerosis and its complications including but not limited to myocardial infarction, stroke and peripheral vascular disease comprising administering to an animal or human an amount of a substance sufficient to decrease or inhibit synthesis of testosterone.

---

#### REMARKS

This request for continued examination is being filed in view of the following statement in the Office Action of December 20, 2001 holding that the proposed Amendment would not be entered because: